

AMENDMENT

In the claims

Please amend the claims as follows:

sub D1
C1
13. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated Varicella Zoster Virus IE63 protein or a fragment or derivative thereof and a pharmaceutically acceptable excipient, wherein the composition induces an immunoprotective response without significant, adverse side effects.

14. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection, comprising administering to a patient a pharmaceutical composition comprising an isolated nucleic acid encoding IE63 or a fragment or derivative thereof, wherein the composition induces an immunoprotective response without significant, adverse side effects.

sub D1
C2
16. A method of treating a patient suffering from or susceptible to Varicella Zoster virus infection as claimed in claim 15, wherein the other VZV antigens are selected from the group, gpI, gpII, gpIII, gpIV, gpV or IE62 or immunological functional derivative thereof.

sub D1
C3
20. A method of producing a pharmaceutical composition comprising an isolated Varicella Zoster virus IE63 protein or fragment or derivative thereof, or an isolated nucleic acid encoding a Varicella Zoster virus IE63 protein or fragment or derivative thereof, comprising mixing said protein or fragment or derivative thereof or said nucleic acid with a pharmaceutically acceptable excipient.

REMARKS

Claims 13-21 are pending in this application. Claims 13-21 stand rejected under 35 U.S.C. §112, second paragraph, and Claims 13-16 and 20 stand rejected under 35 U.S.C. §102(b) as anticipated by Nader et al. Applicants acknowledge the Examiner's view that Claims 17-19 and 21 are free from the prior art.